Search





Search





Markets
/
Stocks
/
nasdaq-piii
/

P3 Health Partners Inc

PIII

Add to Watchlist

11.350USD

+7.320+181.64%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

37.30MMarket Cap

0.04P/E TTM



P3 Health Partners Inc

11.350

+7.320+181.64%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of P3 Health Partners Inc

Currency: USD Updated: 2026-05-14

Key Insights

P3 Health Partners Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 182 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

P3 Health Partners Inc's Score

Industry at a Glance

Industry Ranking

182 / 382

Overall Ranking

326 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

P3 Health Partners Inc Highlights

StrengthsRisks

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 15.22% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.46B.

Overvalued

The company’s latest PE is 0.01, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 396.96K shares, decreasing 49.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.500

Target Price

-1.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-14

The current financial score of P3 Health Partners Inc is 6.39, ranking 246 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 386.39M, representing a year-over-year increase of 3.53%, while its net profit experienced a year-over-year increase of 105.97%.

Score

Industry at a Glance

Previous score

6.39

Change



Financials

4.23

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.71

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

P3 Health Partners Inc's Company Valuation

Currency: USD Updated: 2026-05-14

The current valuation score of P3 Health Partners Inc is 7.63, ranking 91 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.01, which is 0.00% below the recent high of 0.01 and 15484.00% above the recent low of -2.31.

Score

Industry at a Glance

Previous score

7.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 182/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-14

The current earnings forecast score of P3 Health Partners Inc is 7.33, ranking 293 out of 382 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.50 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.500

Target Price

-1.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

P3 Health Partners Inc

PIII

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-14

The current price momentum score of P3 Health Partners Inc is 3.75, ranking 361 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.85 and the support level at 2.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.43

Change

0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

0.225

Buy

RSI(14)

71.926

Buy

STOCH(KDJ)(9,3,3)

70.743

Neutral

ATR(14)

0.343

High Vlolatility

CCI(14)

130.047

Buy

Williams %R

21.522

Buy

TRIX(12,20)

1.289

Sell

StochRSI(14)

91.557

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

3.740

Buy

MA10

3.381

Buy

MA20

3.065

Buy

MA50

2.889

Buy

MA100

2.791

Buy

MA200

5.176

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of P3 Health Partners Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 11.99%, representing a quarter-over-quarter increase of 9.17%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Chicago Pacific Founders UGP LLC

1.54M

Alyeska Investment Group, L.P.

137.41K

-24.05%

Bacchus (Amir)

45.13K

Abdou (Sherif)

32.16K

Trinity Financial Advisors LLC

28.66K

+7.42%

Geode Capital Management, L.L.C.

21.41K

+5.06%

Wasson (Gregory D)

21.36K

+10.33%

Corient Private Wealth LLC

20.84K

-41.09%

Risk Assessment

Currency: USD Updated: 2026-05-14

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of P3 Health Partners Inc is 2.58, ranking 209 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.